India, Aug. 15 -- Tonix Pharmaceuticals Holding Corp. (TNXP) is expected to hear from the FDA its decision on the investigational drug TNX-102 SL, proposed for the management of fibromyalgia, today.
Fibromyalgia is a chronic pain disorder resulting from amplified sensory and pain signaling within the central nervous system. This condition afflicts an estimated 6-12 million adults in the U.S., approximately 90% of whom are women. Symptoms of fibromyalgia include chronic widespread pain, nonrestorative sleep, fatigue, and morning stiffness. Other associated symptoms include cognitive dysfunction and mood disturbances, including anxiety and depression. Pfizer's Lyrica, Lilly's Cymbalta, and AbbVie's Savella are some of the FDA-approved drugs ...